DBV Technologies (NASDAQ:DBVT) Given Market Outperform Rating at JMP Securities

DBV Technologies (NASDAQ:DBVT)‘s stock had its “market outperform” rating reaffirmed by investment analysts at JMP Securities in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock. JMP Securities’ price target would suggest a potential upside of 194.12% from the stock’s current price.

DBVT has been the topic of several other research reports. HC Wainwright lifted their target price on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. StockNews.com began coverage on shares of DBV Technologies in a report on Sunday. They set a “hold” rating on the stock.

DBV Technologies Trading Down 2.6 %

Shares of DBVT traded down $0.09 on Tuesday, reaching $3.40. The company’s stock had a trading volume of 14,644 shares, compared to its average volume of 45,642. The stock has a market capitalization of $69.94 million, a PE ratio of -0.78 and a beta of 0.64. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $10.70. The firm has a fifty day moving average of $3.46 and a 200-day moving average of $4.06.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.